Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_assertion type Assertion NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_head.
- NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_assertion description "[PLTP activity and apoE were measured in patients with type 2 diabetes from the DALI (Diabetes Atorvastatin Lipid Intervention) Study, a 30-week randomized double-blind placebo-controlled trial with atorvastatin (10 and 80 mg daily).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_provenance.
- NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_assertion evidence source_evidence_literature NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_provenance.
- NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_assertion SIO_000772 16644710 NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_provenance.
- NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_assertion wasDerivedFrom befree-20140225 NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_provenance.
- NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_assertion wasGeneratedBy ECO_0000203 NP567916.RAIlNzGEr0wIWRVCrzENGv7WX-EJJLg11iZm9yWs3kn2M130_provenance.